Attendee search 

Sixty Degree Capital Inc. is a Toronto based venture capital investor with US$200MM+ under management investing across North America and Asia. We are dedicated to building strong, long-term relationships with our partners and investors within our industries of focus. Our Toronto office has been actively investing in Healthcare related sectors in the past several years. By partnering with top tier lead investors such as Lumira Ventures, Versant Ventures, Google Ventures, iNovia Capital etc., we have deployed our capital into some exciting North American companies including Schrödinger (Drug discovery platform), Turnstone Biologics and Northern Biologics (Immuno Oncology therapeutics), as well as Antios Therapeutics (HBV innovative therapy). As a growth to late stage investor, our initial cheque size ranges from USD 3 to 5m with reserve of USD 10~20m.

TF Capital focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.

专注于儿科品种

LinkedUp Bio, pioneered a novel antibody drug discovery engine that is dedicated to developing novel biological therapeutics for diseases that have limited or no successful treatment.
The gamechanger element is that we can scree the entire natural immune repertoire with unprecedented speed and scales and identified hits rapidly and efficiently, thereby greatly increasing the success rate of potential therapeutics for targets that are hard to drug.

AbLink Platform: Screening the entire immune repertoire for more efficient antibody discovery
LInkedUp Bio is using microfluidic device to enable single B cell encapsulation, and subsequently, extract the information of heavy chain and light chain of antibody from tens of millions of B cells and then transferred them into our in-house engineered yeast system. These antibody copies in the yeast cells maintained their natural heavy chaiin and light chain pair, and good biophysical stabilities of the original B cells. Our yeast strain has both display and secretion mode which enables quick chacterization of the potential hits, eliminating the step for mamamlian expression for further hits validation, a typical bottleneck for many single B cell platfrom.

The AbLink Platform is the only platform allowing comprehensive screening of the natural antibody repertoire. This results in at least 100 times more hits than hybridoma and other single B cell platforms. Other benefits include more extensive epitope coverage, more unique and rare sequences & diversity, higher affinity, and functionality. Currently the platform gathered a great deal of interest in industry as we already collaborated with two biopharmas and several others are in the middle of conversation.

LUB-001 : Tackling malignant melanoma and solid tumors
LinkedUp Bio’s first target indication is malignant melanoma, one of the deadliest forms of human cancer, due to the high incidence of metastases and drug resistance. Extensive research supports the role of a new target X for malignant melanoma, potentially affecting tumor growth, survival and metastasis. However, due to the limitations of traditional antibody discovery technologies and the complex structure of the target, there have been numerous antibody candidates that showed limited efficacy in inhibition of tumor growth, never matched the high expectation and promise of a breakthrough treatment.
LinkedUp developed a novel antibody clone for this target X and in vitro data demonstrated drastically improvement of the ability of the immune system to attack the tumor cells. LinkedUp Bio’s approach can provide a novel promising treatment for many different types of cancer, such as triple negative breast cancer, glioblastoma, hepatocellular carcinoma, and more.
LUB-002: Tackling congenital muscular dystrophy
Alpha Dystrolycanopathy is a clinically and genetically heterogeneous group of muscular dystrophies with the defective matriglycan which links the muscle cells with extracellular matrix . The cause of the defection involved more than 18 genes, and manifested various degree of severity in clinical symptoms. Currently there no effective therapy for this group of diseases. Novel strategies like antisense, AAV gene therapy, enzyme replace can only address one kind gene a time, making a significant commercial challenge. We propose a novel bispecific antibody approach that functions as a surrogate molecular linker to reconnect extracelluar matrix and the muscle cells to ameliorate sarcolemmal fragility, a primary pathology in patients with alpha-dystroglycan- related muscular dystrophies.

We are currently seeking fund to move our program forward and expand our team.

Team:
Greg Li, Co-founder, President
Stephen Gillies, Co-founder, CSO
Tao Wang, Co-founder, Vice President of Antibody Discovery

Jason Lavinder, Cofounder, Advisory Board

Zhongyuan Yuzi is a provincial investment company and a province-managed state-owned corporation, the establishment of which is approved by Henan provincial government, with the function of serving the strategy and market operation and the role in safeguarding the investment of provincial infrastructure projects,cultivating and guiding the strategic emerging industries, leading and inciting the social investments.

Currently, we are looking for leading pharmaceutical companies as long-term financial or strategic investment partnerships.

河南省骨干企业。先后发起设立了3000亿元规模的河南省新型城镇化发展基金、1000亿元规模的“一带一路（河南）发展基金”、 1000亿元规模的全省现代服务业基金、50亿元规模的PPP开发性基金。

截至2019年12月底，豫资控股集团注册资金100亿元，合并总资产2734.9亿，净资产845.57亿。豫资控股集团子公司及孙公司（并表子公司）共计67家，其中二级子公司11家，三级子公司56家。国内评级AAA、国际评级A2。

Heathcare PE fund

Pharmaceutical

Medical Machine investment

focus on early-stage life science investment